{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:15:23Z","timestamp":1787019323215,"version":"build-2736575974"},"reference-count":42,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hydrofluoroolefin-1234ze (HFO-1234ze) is a next-generation propellant with 99.9% lower global warming potential (GWP) than hydrofluoroalkane-134a (HFA-134a).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>We report systemic and lung exposure bioequivalence for budesonide\/glycopyrrolate\/formoterol fumarate (BGF) components with HFO-1234ze versus HFA-134a.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>These phase I, randomized, double-blind, single-dose, 3-way cross-over trials in healthy adults included three phases (screening; three single-dose treatment periods with 3- to 7-day washouts; follow-up).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Participants were randomized to four BGF inhalations (160\/9\/4.8\u2009\u00b5g\/actuation) with test (HFO-1234ze) or reference (HFA-134a) treatments in one of three sequences, with HFA-134a administered during two of the three treatment periods. For lung exposure, oral activated charcoal was administered before and after treatment. Bioequivalence was considered established if the 90% confidence interval (CI) for the geometric mean ratio (GMR) was within 80%\u2013125% (or expanded limits, if appropriate) for maximum plasma concentration (Cmax), area under the plasma concentration\u2013curve from time zero to the last quantifiable concentration (AUClast) and AUC from time zero to infinity (AUCinf; US approach only).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Bioequivalence criteria were met across BGF components. The 90% CI for the GMR was within 80%\u2013125% (or expanded limits) for HFO-1234ze versus HFA-134a, for systemic (GMR: Cmax, 85.41\u201399.29; AUClast, 95.74\u2013102.48; AUCinf, 90.72\u2013102.58) and lung (GMR: Cmax, 93.39\u2013104.24, AUClast, 97.02\u2013107.76; AUCinf, 101.45\u2013112.22) exposure. No serious adverse events were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Total systemic and lung exposure to all BGF components met bioequivalence criteria for HFO-1234ze versus HFA-134a, with no new or unexpected safety findings. The near-zero GWP HFO-1234ze propellant is a viable replacement for HFA-134a.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>NCT05569421 (clinicaltrials.gov\/study\/NCT05569421) and NCT05477108 (clinicaltrials.gov\/study\/NCT05477108).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17534666261417149","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:24:58Z","timestamp":1770902698000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Bioequivalence of budesonide\/glycopyrrolate\/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies"],"prefix":"10.1177","volume":"20","author":[{"given":"Artur","family":"Bednarczyk","sequence":"first","affiliation":[{"name":"Respiratory and Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca Pharma Poland, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4660-5040","authenticated-orcid":false,"given":"Magnus","family":"Aurivillius","sequence":"additional","affiliation":[{"name":"Respiratory and Immunology, Global Patient Safety, Biopharmaceuticals R&amp;D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep","family":"Jassal","sequence":"additional","affiliation":[{"name":"Respiratory and Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir","family":"Shah","sequence":"additional","affiliation":[{"name":"Respiratory and Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Raphiou","sequence":"additional","affiliation":[{"name":"Respiratory and Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Petullo","sequence":"additional","affiliation":[{"name":"Respiratory and Immunology, Biometrics, Biopharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Xu","sequence":"additional","affiliation":[{"name":"Respiratory and Immunology, Biometrics, Biopharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Heijer","sequence":"additional","affiliation":[{"name":"Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&amp;D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klementyna","family":"Sychowicz","sequence":"additional","affiliation":[{"name":"Respiratory and Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca Pharma Poland, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Collison","sequence":"additional","affiliation":[{"name":"Respiratory and Immunology, Clinical Operations, Biopharmaceuticals R&amp;D, AstraZeneca, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Silva","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&amp;D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendar","family":"Reddy","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&amp;D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Han","sequence":"additional","affiliation":[{"name":"Parexel, Glendale, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Goldwater","sequence":"additional","affiliation":[{"name":"Parexel, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gillen","sequence":"additional","affiliation":[{"name":"Creek Lane PK, LLC, Waterford, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Patel","sequence":"additional","affiliation":[{"name":"Respiratory &amp; Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca, Academy House, 136 Hills Road, Cambridge CB2 8PA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/05\/GINA-2024-Strategy-Report-24_05_22_WMS.pdf (2024 accessed 26 November 2024)."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00166410"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-013-0063-x"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1586\/17476348.2014.905916"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02106-2021"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclepro.2019.117733"},{"key":"e_1_3_4_8_2","unstructured":"United Nations Environment Programme. The Kigali Amendment (2016): the amendment to the Montreal Protocol agreed by the Twenty-Eighth Meeting of the Parties https:\/\/ozone.unep.org\/treaties\/montreal-protocol\/amendments\/kigali-amendment-2016-amendment-montreal-protocol-agreed (2016 accessed 2025 Mar 5)."},{"key":"e_1_3_4_9_2","unstructured":"United Nations Environment Programme. The Montreal protocol on substances that deplete the ozone layer https:\/\/ozone.unep.org\/treaties\/montreal-protocol (2020 accessed 5 June 2024)."},{"key":"e_1_3_4_10_2","unstructured":"European Medicines Agency. Trixeo Aerosphere. Summary of product characteristics https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trixeo-aerosphere-epar-product-information_en.pdf (2020 accessed 23 Sep 2025)."},{"key":"e_1_3_4_11_2","unstructured":"US Food and Drug Administration. Breztri Aerosphere\u2122 highlights of prescribing information https:\/\/den8dhaj6zs0e.cloudfront.net\/50fd68b9-106b-4550-b5d0-12b045f8b184\/9d44f9af-438a-448b-bb5c-dae506e17e49\/9d44f9af-438a-448b-bb5c-dae506e17e49_viewable_rendition__v.pdf (2022 accessed 9 July 2025)."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916046"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30327-8"},{"key":"e_1_3_4_14_2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. 2025 GOLD Report: Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease https:\/\/goldcopd.org\/2025-gold-report\/ (2025 accessed 23 Sep 2025)."},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/17534666211034329"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202006-2618OC"},{"key":"e_1_3_4_17_2","unstructured":"Honeywell International I. Honeywell and Recipharm to speed development of inhalers with a near-zero global warming potential propellant https:\/\/www.honeywell.com\/us\/en\/press\/2023\/08\/honeywell-and-recipharm-to-speed-development-of-inhalers-with-a-near-zero-global-warming-potential-propellant (2023 accessed 23 June 2025)."},{"key":"e_1_3_4_18_2","unstructured":"Intergovernmental Panel on Climate Change. Working Group I Sixth Assessment Report https:\/\/www.ipcc.ch\/report\/ar6\/wg1\/downloads\/report\/IPCC_AR6_WGI_Chapter_07_Supplementary_Material.pdf (2021 accessed 10 June 2025)."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S262141"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2023.102245"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03635-5"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(99)90302-5"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2001.01304.x"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.98.12061340"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2014.1195"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04024.x"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1113-z"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.585"},{"key":"e_1_3_4_29_2","unstructured":"United States Food and Drug Administration. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA guidance for industry https:\/\/www.fda.gov\/media\/87219\/download (2021 accessed 5 March 2025)."},{"key":"e_1_3_4_30_2","unstructured":"European Medicines Agency. Guideline on the investigation of bioequivalence https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf (2010 accessed 5 March 2025)."},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2018.03.001"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.03.007"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.02.012"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2018.05.001"},{"key":"e_1_3_4_35_2","first-page":"73","article-title":"Sample sizes for designing bioequivalence studies for highly variable drugs","volume":"15","author":"Tothfalusi L","year":"2012","unstructured":"Tothfalusi L, Endrenyi L. Sample sizes for designing bioequivalence studies for highly variable drugs. J Pharm Pharm Sci 2012; 15: 73\u201384.","journal-title":"J Pharm Pharm Sci"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.3389\/fenvs.2023.1297920"},{"key":"e_1_3_4_37_2","article-title":"S60 A new medical propellant HFO-1234ze(E): reducing the environmental impact of inhaled medicines [abstract]","volume":"77","author":"Hargreaves C","year":"2022","unstructured":"Hargreaves C, Budgen N, Whiting A, et al. S60 A new medical propellant HFO-1234ze(E): reducing the environmental impact of inhaled medicines [abstract]. Thorax 2022; 77: A38\u2013A39.","journal-title":"Thorax"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S374670"},{"key":"e_1_3_4_39_2","first-page":"56","article-title":"Variability of forced oscillation (Siemens Siregnost FD 5) measurements of total respiratory resistance in patients and healthy subjects","volume":"71","author":"Gimeno F","year":"1993","unstructured":"Gimeno F, van der Weele LT, Ko\u00ebter GH, et al. Variability of forced oscillation (Siemens Siregnost FD 5) measurements of total respiratory resistance in patients and healthy subjects. Ann Allergy 1993; 71: 56\u201360.","journal-title":"Ann Allergy"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.85.s1.04"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.105857"},{"key":"e_1_3_4_42_2","volume":"209","author":"Raphiou I","year":"2024","unstructured":"Raphiou I, et al. Am J Respiratory Critical Care Med 2024; 209: A1216.","journal-title":"Am J Respiratory Critical Care Med"},{"key":"e_1_3_4_43_2","volume":"209","author":"Shah M","year":"2024","unstructured":"Shah M, et al. Am J Respiratory Critical Care Med 2024; 209: A3824.","journal-title":"Am J Respiratory Critical Care Med"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666261417149","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17534666261417149","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666261417149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T10:54:56Z","timestamp":1771152896000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17534666261417149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":42,"alternative-id":["10.1177\/17534666261417149"],"URL":"https:\/\/doi.org\/10.1177\/17534666261417149","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/17534666261417149\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261417149\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261417149\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261417149\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261417149\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261417149\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261417149\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261417149\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261417149\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261417149\/v2\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666261417149\/v1\/review3","asserted-by":"object"}]},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"17534666261417149"}}